ÜYÜstün Yılmaz

Üstün Yılmaz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Üstün Yılmaz has a total of 215 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Long-Term Major Adverse Kidney and Cardiovascular Events in Predialysis Chronic Kidney Disease: A Real-World Cohort Study

    by Ayşe Karaduru Avcı, Ayca Inci, Rauf Avcı, Uğur Büyükokudan, Fatih Sargin, Lütfullah Zahit Koç, Üstün Yılmaz

    Background and Objectives: Long-term renal and cardiovascular outcomes represent major clinical burdens in predialysis chronic kidney disease (CKD). This study aimed to evaluate the long-term incidence of and clinical factors associated with major adverse kidney events (MAKEs) and incident major adverse cardiovascular events (MACEs) in patients with predialysis CKD. Materials and Methods: This retrospective cohort included 263 adults with predialysis CKD followed for at least five years. Patients with baseline dialysis, kidney transplantation, coronary artery disease, heart failure, stroke, or malignancy were excluded. MAKE was defined as chronic dialysis, kidney transplantation, or a ≥50% decline in baseline eGFR. MACE comprised nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. Separate multivariable Cox regression models were constructed for MAKE and MACE, with treatment exposures modeled as time-dependent covariates. Fine–Gray competing-risk regression was performed as a sensitivity analysis. Results: During a median follow-up of 2829 days, MAKE occurred in 97 patients (36.9%) and MACE in 53 (20.2%), corresponding to incidence rates of 47.8 and 26.0 per 1000 person-years, respectively. In multivariable Cox models for MAKE, lower baseline eGFR (HR per 10 mL/min/1.73 m2 increase 0.84, 95% CI 0.72–0.98; p = 0.024) and greater albuminuria severity were independently associated with risk. Compared with normal albuminuria, microalbuminuria and macroalbuminuria were associated with approximately fourfold and eightfold higher hazards, respectively (HR 4.15, 95% CI 1.91–9.00; and HR 7.73, 95% CI 4.01–14.90; both p < 0.001). For MACE, older age (HR per 10 years 1.52, 95% CI 1.12–2.06; p = 0.007) and diabetes mellitus (HR 3.00, 95% CI 1.60–5.62; p < 0.001) were independently associated with higher risk, while higher baseline eGFR was associated with lower risk in the treatment-adjusted models (HR per 10 mL/min/1.73 m2 0.76; p = 0.032–0.037). Neither time-dependent SGLT2 inhibitor nor ACE inhibitor/ARB use was significantly associated with MAKE or MACE. Fine–Gray competing-risk analyses yielded broadly consistent results. SGLT2 inhibitor exposure occurred in 75 patients (28.5%), and treatment-related findings should be interpreted cautiously given the limited exposure and observational design. Conclusions: MAKE and MACE were common in predialysis CKD. Lower baseline kidney function and albuminuria severity were associated with adverse kidney outcomes, whereas older age, diabetes mellitus, and lower baseline kidney function were associated with incident cardiovascular events. These findings highlight distinct renal and cardiovascular risk profiles in predialysis CKD.

  • Open Access

    Hyperkalemia Risk After Finerenone Initiation in Diabetic Kidney Disease with Elevated Baseline Potassium: A Multicenter Cohort Study

    by Alper Tuna Güven, Serap Yadigar, Murat Özdede, Suat Akgür, Felemez Arslan, Mehmet Sezen, Büşra Özcan, Elif Yıldırım Ayaz, Betül Doğantekin, İlker Atay, et al.

    Background/Objectives: Finerenone improves cardiovascular and renal outcomes in diabetic kidney disease (DKD), but hyperkalemia remains a key safety concern. Patients with elevated baseline potassium levels (≥4.9 mEq/L) are largely excluded from clinical trials, and real-world data in this population are scarce. Methods: In this retrospective multicenter cohort study derived from the FINE-TURK cohort, adults with DKD who initiated finerenone with baseline potassium ≥ 4.9 mEq/L were included. The primary outcome was clinically significant hyperkalemia (K ≥ 5.5 mEq/L) within three months. Multivariable logistic regression analyses were used to identify associated factors, with multiple sensitivity analyses performed. Results: A total of 166 patients were included, of whom 47 (28.3%) had baseline potassium levels between 5.1 and 5.5 mEq/L. Of the 166 patients, 35 (21.1%) reached the primary outcome, and 10 (6%) patients had follow-up potassium ≥ 6.0 mEq/L. 126 (76.8%) patients required no intervention, 24 (14.6%) were initiated on potassium binders, and finerenone was discontinued in only 12 (7.3%) patients. Lower baseline estimated glomerular filtration rate, baseline urinary albumin, loop diuretic use and 20 mg finerenone dose were associated with the primary outcome. In contrast, baseline potassium was not associated with the primary outcome. Conclusions: In patients with DKD and elevated baseline potassium levels, finerenone initiation was associated with manageable rates of hyperkalemia. Our findings support the cautious use of finerenone in selected patients under close monitoring, as well as highlight the need for a multidimensional approach to hyperkalemia risk assessment.

  • Open Access

    Hyperkalemia Risk and Associated Factors After Finerenone Initiation in Patients with Diabetic Kidney Disease and Elevated Baseline Potassium: A Real-World Cohort Study

    by Alper Tuna Güven, Serap Yadigar, Murat Özdede, Suat Akgür, Felemez Arslan, Mehmet Sezen, Büşra Özcan, Elif Yıldırım Ayaz, Betül Doğantekin, İlker Atay, et al.

    Background/Objectives: Finerenone improves cardiovascular and renal outcomes in diabetic kidney disease (DKD), but hyperkalemia remains a key safety concern. Patients with elevated baseline potassium levels (≥ 4.9 mEq/L) are largely excluded from clinical trials, and real-world data in this population are scarce. Methods: In this retrospective multicenter cohort study derived from the FINE-TURK cohort, adults with DKD who initiated finerenone with baseline serum potassium ≥ 4.9 mEq/L were included. The primary outcome was clinically significant hyperkalemia (CSH) (≥ 5.5 mEq/L) within three months. Multivariable logistic regression analyses were used to identify associated factors, with multiple sensitivity analyses performed. Results: 166 patients were included, of whom 47 (28.3%) had baseline potassium levels between 5.1 to 5.5 mEq/L. Of the 166 patients, 35 (21.1%) developed CSH, and 10 (6%) patients had follow-up potassium ≥ 6.0 mEq/L. 126 (76.8%) patients required no intervention, 24 (14.6%) were initiated on potassium binders, and finerenone was discontinued only in 12 (7.3%) patients. Baseline eGFR, baseline urinary albumin, loop diuretic use and 20mg finerenone dose were associated with CSH. In contrast, baseline serum potassium was not associated with CSH. Conclusions: In patients with DKD and elevated baseline potassium levels, finerenone initiation was associated with manageable rates of hyperkalemia. Our findings support the cautious use of finerenone in selected patients under close monitoring, as well as highlight the need for a multidimensional approach to hyperkalemia risk assessment.

  • Open Access

    Hyperkalemia Risk with Finerenone in Diabetic Kidney Disease: A Real-World Analysis from the FINE-TURK Cohort

    by Murat Özdede, Serap Yadigar, Alper Tuna Güven, Suat Akgür, Felemez Arslan, Mehmet Sezen, Büşra Özcan, Elif Yıldırım Ayaz, Betül Doğantekin, İlker Atay, et al.

    Background: Finerenone is associated with a lower, yet clinically relevant, risk of hyperkalemia compared with steroidal mineralocorticoid receptor antagonists in diabetic kidney disease (DKD) trials. However, real-world data on hyperkalemia and its associated factors are lacking. Methodology: FINE-TURK is a national, observational cohort of DKD patients who were initiated on finerenone. Eligible adults were included; demographic, clinical, and laboratory data were evaluated. The primary outcome (PO) was hyperkalemia risk signal (potassium ≥ 5.0 mEq/L), and the secondary outcome (SO) was clinically meaningful hyperkalemia (potassium ≥ 5.5 mEq/L). Multivariate logistic regression (LR) was used to define features associated with both PO and SO. LR, random forest (RF), gradient boosting, and CatBoost classifiers were used to define important features associated with the PO. Results: 699 patients were included. 259 (37.1%) reached the PO, and 51 (7.3%) reached the SO. Baseline potassium and estimated glomerular filtration rate (eGFR) were the most important variables associated with both outcomes and were consistently identified as the top features across all models. Thiazide use, presence of diabetic retinopathy, and diabetes duration were also associated with the PO. LR demonstrated the highest recall; random forest achieved the highest precision in performance. Discussion: Real-world data suggest that the risk of clinically meaningful hyperkalemia is similar to that in the clinical trials. In parallel with the safety analysis of clinical trials, baseline potassium and eGFR were consistently the most important factors associated with hyperkalemia risk.


  • Serum uric acid-creatinine ratio as a marker of chronic kidney disease: a retrospective observational study

    by Ayşe Karaduru Avcı, Ayça İnCi, Fatih Sargın, Burak Turgut, Esra Rızaoğulları Güzel, Semih Gül, Üstün Yılmaz

    Serum uric acid (SUA) level has been associated with the progression of chronic kidney disease (CKD), but the role of the SUA/creatinine (SUA/Cre) ratio remains unclear. This study aimed to evaluate whether the SUA/Cre ratio is superior to isolated SUA as a marker for CKD. A retrospective observational study including 524 participants was conducted to compare SUA and SUA/Cre ratio in groups with and without CKD. Participants were categorized into 3 groups according to CKD stage: no CKD (n = 84), CKD stage 1-2 (n = 124), and CKD stage 3-4 (n = 316). Multivariate and receiver operating characteristic (ROC) analyses were performed to assess the association of SUA and SUA/Cre ratio with the presence of CKD. According to the ROC curve, SUA level showed a stronger correlation than the SUA/Cre ratio (area under the curve [AUC] = 0.768 vs AUC = 0.261; p < .001). Although both the SUA/Cre ratio and SUA level were associated with renal dysfunction, SUA was found to be a better marker of CKD.


  • Epidemiological analysis of the victıms wıth crush syndrome in earthquakes of southeastern Turkey

    by Ilyas Ozturk, Ozkan Gungor, Savas Ozturk, Refik Olmaz, Ayse Jini Gunes Keskin, Ismail Kocyigit, Murat Hayri Sipahioglu, Fatih Dede, Sena Ulu, Kenan Turgutalp, et al.

    Background Each year, millions face natural disasters, encountering mass fatalities and severe medical issues such as crush injuries and crush syndrome. Crush syndrome, marked by acute kidney injury (AKI) and hyperkalemia, correlates with mortality. This study focuses on presenting epidemiological data on kidney disease resulting from the February 6, 2023 earthquakes centered in Kahramanmaras. Methods This retrospective analysis included patients diagnosed with crush syndrome after the 2023 Kahramanmaras earthquakes, treated in regional hospitals or referred elsewhere in Turkey. Patient data were documented using the web-based system developed by the Turkish Nephrology Association Renal Disaster Working Group. Results Of the 1024 analyzed patients from 46 centers, 515 (50.3%) were women. The mean age was 41 ± 16 years, with a median duration of 12 h under rubble, and the median presentation time to the first health facility was 4 h after extrication from the rubble. Upon admission, 79.8% received intravenous fluid therapy, all potassium-free. Initial serum creatinine, K+, and creatinine kinase levels averaged 2.59 ± 2 mg/dl, 5.1 ± 1 mmol/L 38,305 ± 54,303 U/L, respectively. Intensive care unit (ICU) admissions were 53.6%, with mean hospital and ICU stays of 20 and 11 days, respectively. Compartment syndrome occurred in 40.8% of patients, with 75.8% undergoing fasciotomy. Acute kidney injury developed in 67.9% of patients, with 70.3% undergoing hemodialysis, totaling 3016 sessions on 488 patients. The overall in-hospital mortality rate was 9.8%. Conclusion Earthquakes have a significant impact on kidney health. Although our study indicates some progress compared to previous earthquake responses, there remains a crucial need for drills emphasizing post-earthquake initial response, fluid-electrolyte balance management, and emergency dialysis protocols. Graphical abstract


  • Open Access

    Investigation of temporomandibular joint diseases and related factors in hemodialysis patients: a cross-sectional study

    by Mehmet Biricik, Üstün Yılmaz

    Aims: This study aimed to investigate the prevalence of temporomandibular joint diseases (TMD) among hemodialysis (hd) patients and to explore the association between sociodemographic and laboratory parameters and the occurrence of TMD. Methods: A cross-sectional study was conducted involving 81 hd patients. Sociodemographic characteristics and laboratory parameters of the participants were collected. TMD was assessed using the fonseca anamnestic test. Statistical analysis was performed using spss-22. Results: Among the 81 participants, 39 (48.1%) were female and 42 (51.9%) were male, with a mean age of 58.2±15.27 years. TMD was detected in 50 patients (61.7%). Significant associations were found between TMD and the presence of comorbid diseases (p=0.002), low hemoglobin levels (p=0.001), and low albumin levels (p=0.002). Conclusion: the study identified comorbid diseases, low hemoglobin, and low albumin as significant factors associated with TMD in hd patients. These findings suggest that heightened awareness and targeted management of these risk factors may improve clinical outcomes for hd patients with TMD. Enhanced understanding among clinicians regarding the high incidence and related factors of TMD in this patient population could lead to more effective treatment strategies.

  • Open Access

    Crush Syndrome: A Review of Current Knowledge

    by Mehmet Biricik, Üstün Yılmaz, Ahmet Dundar, Enes Karaman, Yakup Şen, Sümeyye Coşgun Baybars, Merve Hacer Duran, Nadide Koca, Gaye Keser, Filiz Namdar Pekiner, et al.

    Sevgili Okuyucularımız , Kitabımızı bilim ışığında değerli çalışmalar yapan dostlarımız sayesinde tamamladık. Her çağda önemini sürdüren sağlık kavramı son birkaç yıldır dünyayı etkisi altına alan covid-19 salgını ve ülkemizin derin bir şekilde etkisini yaşamış olduğu deprem afeti ile önemini bir kez daha ortaya koymuştur. Eğitimin sürekliliğine inanan biz sağlık çalışanları bilgi ile donanmış ve akıl ile kanıta dayalı bilgiyi kullanan toplumların sağlık sınavlarını çok daha az yara alarak ve daha az kayıp ile atlatacağını düşünüyoruz. Bu sebeple kitabın bizim için amacı içindeki bilinen bilgiler ve bilinmeyenler vasıtasıyla okuyucularını uyarmak suretiyle gelecekteki çalışmalara bir parça olsun ışık tutabilmek, karanlığı aydınlatabilmektir. Sunulan kitabımızın kavramasının kolay olması ile tıp, diş hekimliği, eczacılık, veterinerlik fakülteleri bilim insanlarına destek olmasının yanında tüm insanlık için yeni ufuklar açmasını temenni ediyoruz. Sağlık bilimlerinde çalışan bilim insanlarına ve kitabımıza destek veren yazar ekibimize teşekkür ederim. Dr. Enes Karaman Dear Readers, We have completed our book thanks to our friends who do valuable studies in the light of science. The concept of health, which continues to be important in every age, has once again revealed its importance with the covid-19 epidemic that has affected the world for the last few years and the earthquake disaster that our country has experienced deeply. We, the healthcare professionals who believe in the continuity of education, think that societies equipped with knowledge and using intelligence and evidence-based knowledge will pass the health exams with much less injury and loss. For this reason, the aim of the book for us is to shed some light on future studies and to illuminate the darkness by warning its readers through the known information and unknowns in it. We hope that our presented book will be easy to understand and will open new horizons for all humanity as well as supporting scientists from faculties of medicine, dentistry, pharmacy and veterinary medicine. I would like to thank the scientists working in the health sciences and our team of authors who supported our book. Dr. Enes Karaman

  • Open Access

    Gallbladder Stone Prevalence and Related Factors in Predialysis Chronic Kidney Disease Patients

    by Üstün Yılmaz, Ayça İnCi, Ercan Özcan, Semih Gül, Hatice Gizem Berber, Firdevs Pelin Eşkin, Yasin Şahintürk, Ayhan Hilmi Çekin

    Background: The aim of this study was to determine the prevalence and factors associated with gallbladder stone in patients with predialysis chronic kidney disease. Methods: This cross-sectional study retrospectively examined follow-up data of patients with chronic kidney disease between January 2015 and December 2020 at the Health Sciences University Antalya Training and Research Hospital who had undergone abdominal ultrasonography for any reason. Patients with gallbladder stone on abdominal ultrasonography and history of cholecystectomy due to gallbladder stone were identified as the gallstone group. The prevalence of gallbladder stone was determined according to disease stage. Patients with and without gallbladder stone were compared in terms of demographic and clinical characteristics and laboratory parameters that may be associated with the development of gallbladder stone. Results: A total of 511 patients had chronic kidney disease (stages 3, 4, and 5 in 303 [59.3%], 176 [34.4%], and 32 [6.3%], respectively). The gallstone prevalence rates were 25.1%, 30.1%, and 46.9% in stage 3, 4, and 5 chronic kidney disease, respectively, and that in all the patients was 28.2% (95% CI: 24.3-32.3, P = .026). Logistic regression analysis revealed that increased age (odds ratio: 1.045; 95% CI: 1.027-1.063, P < .001) and decreased estimated glomerular filtration rate (odds ratio: 0.974; 95% CI: 0.956-0.991, P = .004) were associated with gallbladder stone. Conclusion: The prevalence of gallbladder stone was high in the predialysis patients with chronic kidney disease and increased with increasing disease stage. High age and low estimated glomerular filtration rate were associated with gallbladder stone formation. Cite this article as: Yılmaz Ü, İnci A, Özcan E, et al. Gallbladder stone prevalence and related factors in predialysis chronic kidney disease patients. Turk J Gastroenterol. 2022;33(9):760-766.